Viridian Therapeutics, Inc. (NASDAQ:VRDN) Q1 2024 Earnings Call Transcript

Viridian Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.00079, expectations were $-1.07.

Keep Reading →